← Back to screener

Bicara Therapeutics Inc. BCAX

Rank #1745 · Nasdaq · $0.6B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
43.0
P/E
-8.8
P/B
-4.03
ROE
45.7%
Op. Margin
–%
Debt Ratio
-12%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -8.8x, P/B -4.03x. Ranks in the top 94% of the universe.

Profitability ★★★★★
Excellent

ROE 45.7%. Ranks in the top 9% of the universe.

Safety ★★★★★
Excellent

Debt ratio -12%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Profitability is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024–$-0.0B$-0.1B$-0.1B–-16
2025–$-0.1B$-0.1B$-0.1B–-12

← See the full screener